Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes

Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes

Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers.

Bibliographic Details
Main Authors: Savchenko Liudmyla G., Digtiar Nataliia I., Selikhova Liudmyla G., Kaidasheva Elvira I., Shlykova Oksana A., Vesnina Liudmyla E., Kaidashev Igor P.
Format: Article
Language:English
Published: Sciendo 2019-09-01
Series:Romanian Journal of Internal Medicine
Subjects:
glucagon-like peptide 1 (glp-1)
liraglutide
diabetes
obesity
nf-kb
sirt1
mediators of inflammation
Online Access:https://doi.org/10.2478/rjim-2019-0003

Internet

https://doi.org/10.2478/rjim-2019-0003

Similar Items